Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903734 · ClinicalTrials.gov registry record · Phase 1
An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00903734: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00903734 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00903734, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this screening portion of this clinical research study is to learn if you are eligible to take part in a clinical research study using Tarceva (erlotinib hydrochloride) and either Erbitux (cetuximab), Velcade (bortezomib), or Sprycel (dasatinib). If the results of the screening portion of this clinical research study show that you are eligible to take part in one of the studies described above, the study drug that you will be assigned to take will depend on the results of biomarker analysis performed as a part of the screening tests described below. Biomarkers are chemical "markers" in the blood/tissue that may be related to how your body might react to the study drug.
Interventions
- DRUG Erlotinib Hydrochloride (Tarceva)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00903734
The ClinicalTrials.gov registry entry for NCT00903734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib Hydrochloride (Tarceva) is the first listed.
NCT00903734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00903734 about?
NCT00903734 is a clinical study titled "An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status". The goal of this screening portion of this clinical research study is to learn if you are eligible to take part in a clinical research study using Tarceva (erlotinib hydrochloride) and either Erbitux (cetuximab), Velcade (bortezomib), or Sprycel (dasatinib). If the results of the screening portion ...
What is the current status of trial NCT00903734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00903734?
The interventions under investigation include: Erlotinib Hydrochloride (Tarceva) (DRUG).
Who is sponsoring clinical trial NCT00903734?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.